Treatment cost of narcolepsy with cataplexy in Central Europe
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F16%3A10330165" target="_blank" >RIV/00179906:_____/16:10330165 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.2147/TCRM.S119888" target="_blank" >http://dx.doi.org/10.2147/TCRM.S119888</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/TCRM.S119888" target="_blank" >10.2147/TCRM.S119888</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Treatment cost of narcolepsy with cataplexy in Central Europe
Popis výsledku v původním jazyce
Background: Narcolepsy is a lifelong, rare neurological sleep disorder characterized by chronic, excessive attacks of daytime sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. Objective: The purpose of this study is to specify the treatment costs of patients in Central Europe (Czech Republic), while the attention is mainly paid to the drugs that were fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated, since it incurs a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. Patients and methods: This study monitors the direct costs of the drugs for 13 patients, who represent similar to 1.3% of the total number of diagnosed patients in the Czech Republic, and evaluates the costs associated with their treatment during the period from January 9, 2011 to April 23, 2013. Results: Most of the treatment costs (similar to 80%) were covered by publicly available sources. This finding is also true for the concomitant therapy of comorbidities. Additional payments for the drugs constitute about 20% of the total costs.
Název v anglickém jazyce
Treatment cost of narcolepsy with cataplexy in Central Europe
Popis výsledku anglicky
Background: Narcolepsy is a lifelong, rare neurological sleep disorder characterized by chronic, excessive attacks of daytime sleepiness. This disease is often extremely incapacitating, interfering with every aspect of life, in work and social settings. Objective: The purpose of this study is to specify the treatment costs of patients in Central Europe (Czech Republic), while the attention is mainly paid to the drugs that were fully or partially covered by public health insurance. Furthermore, concomitant therapy is also evaluated, since it incurs a certain financial burden for patients and their family members. On the basis of the calculated costs, impact on the public budget is evaluated. Patients and methods: This study monitors the direct costs of the drugs for 13 patients, who represent similar to 1.3% of the total number of diagnosed patients in the Czech Republic, and evaluates the costs associated with their treatment during the period from January 9, 2011 to April 23, 2013. Results: Most of the treatment costs (similar to 80%) were covered by publicly available sources. This finding is also true for the concomitant therapy of comorbidities. Additional payments for the drugs constitute about 20% of the total costs.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FQ - Veřejné zdravotnictví, sociální lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Therapeutics and Clinical Risk Management
ISSN
1178-203X
e-ISSN
—
Svazek periodika
12
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
NZ - Nový Zéland
Počet stran výsledku
7
Strana od-do
1709-1715
Kód UT WoS článku
000388021300001
EID výsledku v databázi Scopus
2-s2.0-84996806742